Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tenecteplase Thrombolysis as Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours: A Multicenter Randomized Controlled Clinical Trial

NCT07912970 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.

NCT NCT07912970 Not yet recruiting Phase 3 1,266 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07912970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started April 2027. Interventional study, Phase 3, 1,266 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measure: Functional Independence at 90 Days.

How it compares

263 similar trials: same condition (Ischemic Stroke) and phase

Enrollment

This trial
1,266
Middle half
222 to 982
Median
520
Trials with a value
263

Months from start to completion

This trial
35
Middle half
22 to 45.2
Median
29.6
Trials with a value
256

Sites

This trial
1
Middle half
1 to 22
Median
1
Trials with a value
241
Posted results or a linked paper 56% 148 of 263 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tenecteplase Thrombolysis as Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours: A Multicenter Randomized Controlled Clinical Trial
Lead sponsor
Fujian Medical University Union Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
March 1, 2030
Enrollment
1,266 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Ischemic Stroke

Registry terms: acute ischemic stroke, large vessel occlusion

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Fujian Medical University Union Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Tenecteplase Group Experimental Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
Show registry wording

Participants will receive intravenous tenecteplase at a dose of 0.25 mg/kg, with a maximum dose of 25 mg, as a single bolus before interhospital transfer. Interhospital transfer to a thrombectomy-capable stroke center will be initiated immediately after tenecteplase administration. At the receiving center, participants will be evaluated for endovascular therapy and treated according to current clinical guidelines.

Direct-Transfer Group No intervention
Show registry wording

Participants are transferred directly to the receiving stroke center without study-assigned intravenous tenecteplase before transfer. At the receiving center, they are evaluated for endovascular therapy, which is performed if clinically indicated. Participants receive standard medical care according to clinical needs.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Functional Independence at 90 Days Day 90 ± 7 days after randomization
Show registry wording

Proportion of participants with functional independence at 90 days after randomization, defined as a modified Rankin Scale score of 0 to 2. The modified Rankin Scale ranges from 0 to 6, with lower scores indicating less disability.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Tenecteplase 1 Orange Book patent
    • US 5385732; expires June 2, 2014; assignee Genentech

Lead sponsor's other trials

Fujian Medical University Union Hospital, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.